Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Resonance Health Ltd ( (AU:RHT) ).
Resonance Health has appointed Michael Sistenich and David Fuller as non-executive directors as part of its ongoing board renewal program aimed at supporting strategic growth. The company said the additions bolster expertise in capital markets, clinical development, regulatory strategy, and global commercialisation.
Sistenich brings more than 25 years’ experience across healthcare, artificial intelligence, life sciences, and institutional investing, including ASX leadership roles and extensive capital markets and medtech exposure. Fuller adds over 30 years of international pharmaceutical and clinical development experience, with a strong track record in guiding drugs from pre-clinical stages through global regulatory approvals and commercialisation.
The board changes are intended to strengthen governance and execution capability as Resonance Health pursues expansion in healthcare technology and related services. Investors and partners are likely to view the appointments as reinforcing the company’s ability to navigate capital markets, run complex clinical programs, and accelerate commercial opportunities in key therapeutic areas.
More about Resonance Health Ltd
Resonance Health Ltd is an Australian medical technology company specialising in healthcare imaging and diagnostic solutions, with a focus on leveraging advanced technologies for clinical decision support. The company targets global healthcare markets, working with pharmaceutical, biotechnology, and clinical research organisations to support drug development and patient management.
Average Trading Volume: 371,533
Technical Sentiment Signal: Sell
Current Market Cap: A$20.99M
See more data about RHT stock on TipRanks’ Stock Analysis page.